ABCD方案治疗复发/难治性多发性骨髓瘤的效果(4)
[14] Dimopoulos MA，Goldschmidt H，Niesvizky R，et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma(ENDEAVOR)：an interim overall survival analysis of an open-label，randomised，phase 3 trial [J]. Lancet Oncol ......
您现在查看是摘要页，全文长 2048 字符。